Aspirin - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for aspirin and what is the scope of freedom to operate?
Aspirin
is the generic ingredient in fifty-three branded drugs marketed by Hesp, Plx Pharma, Bayer, Savage Labs, Lgm Pharma, Nostrum Labs Inc, Watson Labs, Allergan, Sandoz, Actavis Elizabeth, Fosun Pharma, Halsey, Hikma Intl Pharms, Ivax Pharms, Puracap Pharm, Quantum Pharmics, Strides Pharma, Lannett, Dr Reddys Labs Sa, Esjay Pharma, Stevens J, Sun Pharm Industries, Bausch, Galt Pharms, Alra, Xanodyne Pharm, Ivax Sub Teva Pharms, Teva, Chartwell Rx, Genus, Novast Labs, Oxford Pharms, Meda Pharms, Ingenus Pharms Nj, Boehringer Ingelheim, Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Endo Operations, Glenmark Speclt, Micro Labs, Sun Pharm, Zydus Pharms, Schwarz Pharma, Abbott, Par Pharm, Medpointe Pharm Hlc, Mcneil, Robins Ah, Genus Lifesciences, Actavis Labs Fl Inc, Epic Pharma Llc, Roxane, Sanofi Aventis Us, Bristol Myers Squibb, and Aaipharma Llc, and is included in eighty-nine NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Aspirin has twenty patent family members in nine countries.
There are twenty-two drug master file entries for aspirin. One supplier is listed for this compound. There is one tentative approval for this compound.
Summary for aspirin
International Patents: | 20 |
US Patents: | 6 |
Tradenames: | 53 |
Applicants: | 58 |
NDAs: | 89 |
Drug Master File Entries: | 22 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 136 |
Clinical Trials: | 1,599 |
Patent Applications: | 6,580 |
Drug Prices: | Drug price trends for aspirin |
Drug Sales Revenues: | Drug sales revenues for aspirin |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for aspirin |
What excipients (inactive ingredients) are in aspirin? | aspirin excipients list |
DailyMed Link: | aspirin at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for aspirin
Generic Entry Date for aspirin*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for aspirin
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Zunyi Medical College | Phase 4 |
Assistance Publique Hopitaux De Marseille | N/A |
Indian Council of Medical Research | Phase 3 |
Generic filers with tentative approvals for ASPIRIN
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 325MG;40MG | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | 81MG;40MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for aspirin
Drug Class | Nonsteroidal Anti-inflammatory Drug Platelet Aggregation Inhibitor |
Mechanism of Action | Cyclooxygenase Inhibitors |
Physiological Effect | Decreased Platelet Aggregation Decreased Prostaglandin Production |
Medical Subject Heading (MeSH) Categories for aspirin
US Patents and Regulatory Information for aspirin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | PROPOXYPHENE COMPOUND 65 | aspirin; caffeine; propoxyphene hydrochloride | CAPSULE;ORAL | 080044-002 | Sep 16, 1983 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Epic Pharma Llc | OXYCODONE AND ASPIRIN | aspirin; oxycodone hydrochloride | TABLET;ORAL | 040910-001 | Jul 16, 2020 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET;ORAL | 021387-001 | Jun 24, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ivax Pharms | BUTALBITAL, ASPIRIN AND CAFFEINE | aspirin; butalbital; caffeine | TABLET;ORAL | 085441-002 | Oct 31, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for aspirin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | ⤷ Sign Up | ⤷ Sign Up |
Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for aspirin
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 340951 | PORTADORES DEPENDIENTES DEL PH PARA LA LIBERACION DIRIGIDA DE PRODUCTOS FARMACEUTICOS A LO LARGO DEL TRACTO GASTROINTESTINAL, COMPOSICIONES DE LOS MISMOS, Y FABRICACIÓN Y USO DE LAS MISMAS. (pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME.) | ⤷ Sign Up |
Australia | 2012315545 | pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same | ⤷ Sign Up |
Canada | 2850187 | ⤷ Sign Up | |
Canada | 2850187 | VECTEURS DEPENDANT DU PH POUR LIBERATION CIBLEE DE PRODUITS PHARMACEUTIQUES DANS LE TUBE DIGESTIF, COMPOSITIONS PREPAREES A PARTIR DE CEUX-CI, ET LEUR FABRICATION ET LEUR UTILISATION (PH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for aspirin
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0984957 | 122012000017 | Germany | ⤷ Sign Up | PRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812 |
0984957 | 2012/048 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.